Why AstraZeneca and J&Jâs Vaccines, In Use Elsewhere, Are Still on Hold in America
Covid has pressed the Food and Drug Administration into its fastest vaccine reviews ever â which are still painfully slow, critics say.
Drugs
561-580 of 1,318 results
-
-
After Billions of Dollars and Dozens of Wartime Declarations, Why Are Vaccines Still in Short Supply?
The Trump and Biden administrations both imposed wartime production requirements. But industry experts say the vast quantities of raw materials and specialty equipment needed for billions of newfangled vaccines have required herculean logistical efforts.
By Rachana Pradhan and Arthur Allen -
KHNâs âWhat the Health?â: Open Enrollment, One More Time
Keeping a campaign promise, President Joe Biden has reopened enrollment for health coverage under the Affordable Care Act on healthcare.gov â and states that run their own health insurance marketplaces followed suit. At the same time, the Biden administration is moving to revoke the Trump administrationâs permission for states to impose work requirements for some adults on the Medicaid health insurance program. Alice Miranda Ollstein of Politico, Kimberly Leonard of Business Insider and Rachel Cohrs of Stat join KHNâs Julie Rovner to discuss these issues and more. Also, Rovner interviews medical student Inam Sakinah, president of the new group Future Doctors in Politics.
-
Can Pfizer and Moderna End the Pandemic by Sharing Their Vaccine Designs? It’s Not that Simple
Industry experts say itâs highly unlikely that dozens of pharmaceutical companies that arenât already producing covid vaccines stand ready to do so.
-
As Drug Prices Keep Rising, State Lawmakers Propose Tough New Bills to Curb Them
The measures would impose taxes on increases in the price of drugs that donât reflect improved clinical value and set the rates paid by state-run and commercial health plans to a benchmark based on prices in Canada.
By Harris Meyer -
Farmworker Camps to Urban Tent Cities: Tailoring Vaccine Info to Where Itâs Most Needed
Concerns arising in western North Carolina provide a window into the challenges facing health workers across the country as they seek to persuade vulnerable populations to be inoculated against covid.
-
KHNâs âWhat the Health?â: Covid and Kids
Can schools safely reopen before all teachers and staffers are vaccinated against covid? And whatâs the best way to communicate that science â and scientific recommendations â change and evolve? Also, get ready for a redo of open enrollment for Affordable Care Act coverage, this time with help and outreach to find those eligible. Margot Sanger-Katz of The New York Times, Alice Miranda Ollstein of Politico and Anna Edney of Bloomberg News join KHNâs Julie Rovner to discuss these issues and more.
-
100 Million Covid Shots in 100 Days Doesnât Get Us Back to Normal
President Joe Bidenâs promise to reach this milestone is an important step forward in vaccine rollout. But it is only the beginning of the sweeping vaccination effort required.
-
When Your Chance for a Covid Shot Comes, Donât Worry About the Numbers
The Johnson & Johnson vaccine that the FDA cleared Saturday was 66% effective overall in preventing moderate to severe covid, while the Pfizer and Moderna vaccines were more than 90% effective. But the numbers arenât exactly comparable. And all three shots prevent hospitalization and death.
By Arthur Allen and Liz Szabo -
States Move Ahead With Canada Drug Importation While Awaiting Signal From Biden
As president, Donald Trump encouraged states to bring in drugs from Canada, where prices are cheaper. Itâs not clear if the new administration will follow suit.
-
KHNâs âWhat the Health?â: The Long Road to Unwinding Trump Health Policies
President Joe Biden signed a pair of health-related executive orders this week that would, among other things, reopen enrollment under the Affordable Care Act and start to reverse former President Donald Trumpâs anti-abortion policies. Meanwhile, Congress remains bogged down with taking up the next round of covid-19 relief. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Shefali Luthra of The 19th join KHNâs Julie Rovner to discuss these issues and more. Plus, for âextra credit,â the panelists recommend their favorite health policy stories of the week they think you should read, too.
-
Remdesivir, Given to Half of Hospitalized Covid Patients in U.S., Is Big Win for Gilead â Boosted by Taxpayers
With U.S. cases skyrocketing, demand for Gileadâs dark horse antiviral is only growing. Biden appointees propose potential legal tactics to tamp down the price for patients.
-
Why Even Presidential Pressure Might Not Get More Vaccine to Market Faster
Even invoking the widely heralded Defense Production Act to pressure drugmakers wouldnât overcome vast obstacles.
-
Health Issues Carried Weight on the Campaign Trail. What Could Biden Do in His First 100 Days?
KHN has teamed up with PolitiFact to track what becomes of President Joe Bidenâs 2020 campaign promises over the next four years. As he moves into the West Wing, what are his chances of making progress on health care?
-
Are Public Health Ads Worth the Price? Not if Theyâre All About Fear
Public service announcements about drug use or other public health problems often fall short, public health marketing experts say, because they incite peopleâs worst fears rather than giving people solutions.
By Eric Berger -
KHNâs âWhat the Health?â: On Capitol Hill, Actions Have Consequences
Several large business groups, including health industry organizations, are cutting off contributions to Republicans who voted against the certification of Joe Bidenâs election even after riots shut down the Capitol on Jan. 6. Meanwhile, the outgoing Trump administration not only approved a Medicaid block grant for Tennessee, but also made it difficult for the incoming Biden administration to undo. Joanne Kenen of Politico, Margot Sanger-Katz of The New York Times and Kimberly Leonard of Business Insider join KHNâs Julie Rovner to discuss these issues and more. Plus, Rovner interviews KHNâs Victoria Knight about the latest KHN-NPR âBill of the Monthâ episode.
-
Delicate Covid Vaccines Slow Rollout â Leading to Shots Given Out of Turn or, Worse, Wasted
âThaw. Rest 15 minutes. Do not shake. Do not refreeze.âDo not shake. Do not refreeze.â Modernaâs vaccine comes with complicated instructions. And both available vaccines are good for only six hours once the vial is open. So at dayâs end, health workers are left to either throw out precious doses or get shots into any arm thatâs available.
-
Is Your Covid Vaccine Venue Prepared to Handle Rare, Life-Threatening Reactions?
More than two dozen people who have received the new covid vaccines in U.S. hospitals and health centers suffered anaphylaxis, a potentially fatal allergic reaction. While such severe reactions are rare, experts warn that the drugstores and drive-thru clinics considered integral to the vaccine rollout must be prepared.
-
Bidenâs First Order of Business May Be to Undo Trumpâs Policies, but It Wonât Be Easy
President Donald Trump made substantial changes to the nationâs health care system using executive branch authority. But reversing policies that Democrats oppose would take time and personnel resources, competing with other priorities of the new administration.
By Julie Rovner -
KHNâs âWhat the Health?â: Georgia Turns the Senate Blue
Democratic victories in two runoff elections in Georgia will give Democrats control of the Senate starting Jan. 20, which means they will be in charge of both houses of Congress and the White House for the first time since 2010. Meanwhile, covid continues to run rampant while vaccine distribution lags. Alice Miranda Ollstein of Politico, Anna Edney of Bloomberg News and Mary Ellen McIntire of CQ Roll Call join KHNâs Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.